Category: News

ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with progressing open-angle glaucoma (OAG) ANN ARBOR, MI – February 13, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel…

ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, MI – February 1, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with…

ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research Oral presentations will focus on latest findings for ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with dry age-related macular degeneration ANN ARBOR, MI – January…

AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study • ONL closed the second tranche of a $46.9 million Series B financing round earlier this year• ONL now preparing IND filing for a Phase 2 study of ONL1204 Ophthalmic Solution• AmbioPharm providing manufacturing support for ONL1204 NORTH AUGUSTA, SC &…

ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer ANN ARBOR, MI – February 9, 2022 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer. As CDO, Dr.…

ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) Phase 1b studies in patients with OAG and GA will evaluate safety, pharmacokinetics and preliminary…

ONL Therapeutics Names Connie Chang as Chief Operating Officer Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration ANN ARBOR, MI – January 19, 2021 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients…